KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Health

MiCo BioMed Creates Kit to Confirm NCoV in an Hour

KoreaTechToday Editor by KoreaTechToday Editor
PUBLISHED: February 5, 2020 UPDATED: February 6, 2020
in Health, Healthcare, MiCo BioMed, South Korea
0
MiCo BioMed logo
MiCo BioMed logo

MiCo BioMed logo

MiCo BioMed Co., Ltd. claimed on Wednesday that it recently developed a highly sensitive rapid molecular diagnostic system to confirm within an hour the 2019 novel coronavirus (2019-nCoV), which was first detected in Wuhan, China.

Mico BioMed, founded in March of 2009, develops and sells medical kits, ultrafast real-time polymerase chain reaction lab chips, ultra-fast lab chip real-time polymerase chain reaction equipment, and other products. The Konex-listed company situated in Seongnam manufactures medical equipment for production in Korea.

CEO Kim Sung-woo, a former Korean American scientist, leads the operations of MiCo BioMed, focusing on immunoassay diagnostics technology, molecular diagnostics, and biological chemistry.

The South Korean health care solutions provider said that the system could immediately detect the 2019-nCoV within one hour. The company will distribute the kit at port quarantine sites and airports besides health care centers.

The biotech company created 30 different varieties of high-risk pathogen diagnostic kits in collaboration with the Korean Centers for Disease Control and Prevention (KCDC). The company used a number of those kits to confirm the presence of bio-terrorism pathogens in vehicles during the 2017 World Cup Games, 2018 Winter Olympics, and 2019 Gwangju Asian Swimming Games.

MiCo BioMed also developed a real-time polymerase chain reaction (PCR) kit to rapidly confirm with high accuracy the 2019-nCoV using the company’s LabChip-powered real-time PCR.

The real-time PCR system is currently awaiting the Emergency Use Approval from the KCDC.

The company said that it expects the systems to be utilized not only at health care facilities but also at harbors and airports as the virus can be rapidly identified within an hour.

In the near future, MiCo BioMed also hopes to apply the kits for other acute infectious diseases such as the Middle East respiratory syndrome (MERS) and the severe acute respiratory syndrome (SARS).

MiCo BioMed recently passed the technical evaluation for relisting on Kosdaq with A grade.

Tags: coronavirushealthcareMiCo BioMedreal-time PCR

Related Posts

Chazm Operator Wins Scale-up TIPS Selection to Expand Automotive Finance AI
MiCo BioMed logo
AI

Chazm Operator Wins Scale-up TIPS Selection to Expand Automotive Finance AI

November 4, 2026
Why the Future of Digital Healthcare May Be Built Around Families, Not Just Patients
MiCo BioMed logo
Healthcare

Why the Future of Digital Healthcare May Be Built Around Families, Not Just Patients

November 1, 2026
Why Healthcare Technology Must Adapt to How People Actually Live
MiCo BioMed logo
Healthcare

Why Healthcare Technology Must Adapt to How People Actually Live

November 1, 2026
The Strategic Investment Trap: What Korean Startup Founders Should Consider Before Taking Corporate VC
MiCo BioMed logo
AI

The Strategic Investment Trap: What Korean Startup Founders Should Consider Before Taking Corporate VC

November 1, 2026
India and South Korea Could Build a New Startup Corridor Around Manufacturing and Technology
MiCo BioMed logo
South Korea

India and South Korea Could Build a New Startup Corridor Around Manufacturing and Technology

November 1, 2026
Why South Korea Could Become a Strategic Growth Partner for Southeast Asian Startups
MiCo BioMed logo
South Korea

Why South Korea Could Become a Strategic Growth Partner for Southeast Asian Startups

November 1, 2026
No Result
View All Result

Most Popular

  • LG Uplus Introduces OpenAI-Powered Agentic Callbot for Customer Phone Support

    0 shares
    Share 0 Tweet 0
  • Samsung and SK Hynix Face New U.S. Licensing Rules for Chinese Chip Plants

    0 shares
    Share 0 Tweet 0
  • Kakao in Talks to Sell Daum, With AI Startup Upstage as Top Contender

    0 shares
    Share 0 Tweet 0
  • Why South Korea’s Hyperconnected Economy Needs a More Integrated Cybersecurity Strategy

    0 shares
    Share 0 Tweet 0
  • Why Kakao Is Shutting Down KakaoTV as YouTube Dominates Korea’s Digital Video Market

    0 shares
    Share 0 Tweet 0
  • Kakao Mobility Faces $10.5 Million Fine for Limiting Competitors’ Access to Taxi Platform

    0 shares
    Share 0 Tweet 0

PRODUCTS

[ads_amazon]

TOPICS

  • Naver
  • Kakao
  • Nexon
  • Netmarble
  • NCsoft
  • Samsung
  • Hyundai

FREE NEWSLETTER

[mc4wp_form id="4726"]

FOLLOW US

  • About Us
  • Cookie policy
  • home
  • homepage
  • mainhome
  • Our Services
  • Privacy Policy
  • Terms of Use

Copyright © 2024 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists

Copyright © 2024 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |